Clinical Trial

Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.

Study acronym: NOBLE
Withdrawn Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
The study was terminated due to administrative reasons following the cancellation of collaboration between the involved parties.
Summary
A Randomized Phase II Study. To assess the difference in objective response rate (ORR) between adult patients with advanced biliary tract cancer assigned to nivolumab plus relatlimab 360 mg/360 mg in combination with GC or nivolumab plus GC as first-line treatment.
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-07-03
notable Enrollment reduced: 76 -> 0 participants 2026-07-03
notable Trial sites reduced: 8 -> 1 locations 2026-07-03
Trial Details
NCT Number NCT07369791
Lead Sponsor National Health Research Institutes, Taiwan
Conditions Advanced Biliary Tract Cancer(BTC)
Start Date 2026-12
Primary Completion 2035-12 (estimated)
Study Completion 2040-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-02